Monday, June 26, 2023 4:30:10 PM
ReShape Lifesciences® Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0
Enhanced Band Reservoir Technology Designed to Improve the Patient Experience
IRVINE, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the submission of a Premarket Approval (PMA) supplement application to the U.S. Food and Drug Administration (FDA) for the company’s next generation, enhanced Lap-Band® 2.0, utilizing a band reservoir technology.
“The PMA supplement submission is a significant milestone and is consistent with our second growth pillar to develop and, ultimately, commercialize new products and therapies,” stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences. “This next generation, enhanced Lap-Band® 2.0 was developed with physician feedback to improve the patient experience. Similar to our current Lap-Band, the Lap-Band 2.0 is adjustable postoperatively to increase or decrease the opening of the band in order to optimize an individual’s comfort, thereby improving therapy effectiveness. However, unique to the Lap-Band 2.0 is an enhanced band reservoir technology that serves as a relief valve, designed to alleviate discomfort from swallowing large pieces of food, that may require in-office band adjustments. We expect feedback from the FDA by year end. If approved, we believe that based on discussions with physicians, that there will be broad adoption by existing Lap-Band® surgeons and surgeons that newly adopt the Lap-Band® 2.0.”
About ReShape Lifesciences®
ReShape Lifesciences® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. ReShapeCare™ is a virtual weight-management program that supports lifestyle changes for all weight loss patients led by board-certified health coaches to help them keep the weight off over time. ReShape Marketplace™ is an online collection of quality wellness products curated for all consumers to help them achieve their health goals. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of Type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.
Forward-Looking Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. Forward-looking statements in this press release include the statements that we expect feedback on the PMA submission from the FDA by year end, and, if approved, that we believe based on physician feedback that there will be broad adoption of the Lap-Band® 2.0 by existing Lap-Band® surgeons and surgeons that newly adopt the Lap-Band® 2.0. These and additional risks and uncertainties are described more fully in the company's filings with the Securities and Exchange Commission, including those factors identified as "risk factors" in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.
CONTACTS
ReShape Lifesciences Investor Contact:
Thomas Stankovich
Chief Financial Officer
949-276-6042
ir@ReShapeLifesci.com
Investor Relations Contact:
Rx Communications Group
Michael Miller
(917)-633-6086
mmiller@rxir.com
https://www.globenewswire.com/newsroom/ti?nf=ODg2NDcxOSM1NjY1MzQxIzIwMDcwNzI=
https://ml.globenewswire.com/media/MDRlMjVmZDUtNDQ4Zi00YTNmLTg4NTItYjNiYWMwMTk3NWY1LTEwMTg2NDU=/tiny/ReShape-Lifesciences-Inc.png
Source: ReShape Lifesciences Inc
© 2023 GlobeNewswire, Inc.
Recent RSLS News
- ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/15/2024 08:05:00 PM
- ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update • GlobeNewswire Inc. • 05/14/2024 12:31:00 PM
- ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 04/01/2024 08:05:00 PM
- ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System • GlobeNewswire Inc. • 03/28/2024 12:31:00 PM
- ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX • GlobeNewswire Inc. • 03/04/2024 01:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 09:19:43 PM
- ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX • GlobeNewswire Inc. • 02/22/2024 01:31:00 PM
- ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX • GlobeNewswire Inc. • 01/24/2024 01:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 09:38:03 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2024 11:11:06 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 01/05/2024 09:14:25 PM
- ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives • GlobeNewswire Inc. • 12/20/2023 01:31:00 PM
- ReShape Lifesciences® Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band® 2.0 FLEX • GlobeNewswire Inc. • 12/12/2023 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/29/2023 09:05:16 PM
- ReShape Lifesciences® Enters into Warrant Exercise Transaction for $1.2 Million in Gross Proceeds • GlobeNewswire Inc. • 11/21/2023 01:06:14 PM
- ReShape Lifesciences® Reports Third Quarter Ended September 30, 2023 Financial Results and 2024 Cost Reduction Plan • GlobeNewswire Inc. • 11/08/2023 09:05:00 PM
- ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate Update • GlobeNewswire Inc. • 11/06/2023 01:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/13/2023 08:42:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/05/2023 08:05:13 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 10/03/2023 01:23:13 PM
- ReShape Lifesciences® Announces Pricing of $3.0 Million Public Offering • GlobeNewswire Inc. • 09/29/2023 04:30:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/27/2023 09:30:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/22/2023 08:02:52 PM
- ReShape Lifesciences® Announces Participation in the LD Micro Main Event XVI • GlobeNewswire Inc. • 09/22/2023 12:31:00 PM
- ReShape Lifesciences® Signs Exclusive License Agreement With Biorad Medisys for Obalon® Gastric Balloon System • GlobeNewswire Inc. • 09/21/2023 12:31:00 PM
FEATURED Integrated Ventures Files Q3/2024 With Mining Revenues Of $1,983,250 And Positive Earnings Of $0.05 Cents Per Share • May 15, 2024 10:30 AM
Swifty Global Announces Impressive Financial Results for Q1 2024 • DRCR • May 15, 2024 10:25 AM
Branded Legacy Inc. Invites Shareholders to Celebrate Milestones at Open House: Announces Share Buyback and Commitment to Authorized Share Count • BLEG • May 15, 2024 8:30 AM
Alliance Creative Group (ACGX) Releases Q1 2024 Financial and Disclosure Report with an 88% increase in Net Income from Q1 2023 to Q1 2024 • ACGX • May 15, 2024 8:30 AM
Category V Biotech, Inc. Announces Letter of Intent to Acquire Genetic Networks, Expanding into Biotechnology Sector • CATV • May 15, 2024 8:00 AM
POET Announces Design Win and Collaboration with Foxconn Interconnect Technology for High-speed AI Systems • POET • May 14, 2024 10:09 AM